Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
29. April 2021 09:50 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven...
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
23. März 2021 07:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven...
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
22. März 2021 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Announces Pricing of Public Offering
16. Februar 2021 06:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
04. September 2019 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
03. September 2019 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
14. August 2019 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
07. August 2019 13:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta
31. Juli 2019 09:20 ET
|
Hepion Pharmaceuticals, Inc.
- Accelerating NASH Research Programs - EDISON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of...
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
29. Juli 2019 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...